BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 20013610)

  • 1. New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour.
    Frank-Raue K; Döhring J; Scheumann G; Rondot S; Lorenz A; Schulze E; Dralle H; Raue F; Leidig-Bruckner G
    Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):550-3. PubMed ID: 20013610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical diagnosis and treatment of familial medullary thyroid carcinoma caused by a p.C618Y RET proto-oncogene mutation in a Chinese pedigree].
    Zhao JQ; Guo L; Qi XP; Chen ZG; Wang KJ; Lou JL; Yu XH; Cheng J; Jin HY; Li XL; Ying RB; Zhang XN
    Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(6):440-4. PubMed ID: 23660264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
    Calva D; O'Dorisio TM; Sue O'Dorisio M; Lal G; Sugg S; Weigel RJ; Howe JR
    Ann Surg Oncol; 2009 Aug; 16(8):2237-44. PubMed ID: 19472011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical strategy in a kindred with a rare RET protooncogene mutation of variable penetrance with regard to multiple endocrine neoplasia.
    Colombo-Benkmann M; Brämswig J; Höppner W; Gellner R; Hengst K; Böcker W; Senninger N
    World J Surg; 2002 Oct; 26(10):1286-90. PubMed ID: 12205548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sporadic hypercalcitoninemia: clinical and therapeutic consequences.
    Scheuba C; Kaserer K; Moritz A; Drosten R; Vierhapper H; Bieglmayer C; Haas OA; Niederle B
    Endocr Relat Cancer; 2009 Mar; 16(1):243-53. PubMed ID: 18987170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma.
    Colombo-Benkmann M; Li Z; Riemann B; Hengst K; Herbst H; Keuser R; Gross U; Rondot S; Raue F; Senninger N; Pützer BM; Frank-Raue K
    Eur J Endocrinol; 2008 Jun; 158(6):811-6. PubMed ID: 18322301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels.
    Machens A; Lorenz K; Dralle H
    Ann Surg; 2009 Aug; 250(2):305-10. PubMed ID: 19638924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medullary thyroid carcinoma.
    Pacini F; Castagna MG; Cipri C; Schlumberger M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):475-85. PubMed ID: 20627492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations?
    Niccoli-Sire P; Murat A; Rohmer V; Gibelin H; Chabrier G; Conte-Devolx B; Visset J; Ronceray J; Jaeck D; Henry JF; Proye C; Carnaille B; Kraimps JL;
    Surgery; 2003 Dec; 134(6):1029-36; discussion 1036-7. PubMed ID: 14668737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prophylactic thyroidectomy in children who are carriers of a multiple endocrine neoplasia type 2 mutation: description of 20 cases and recommendations based on the literature].
    de Groot JW; Links TP; Rouwe CW; van der Wal JE; Hofstra RM; Plukker JT
    Ned Tijdschr Geneeskd; 2006 Feb; 150(6):311-8. PubMed ID: 16503023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
    Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
    Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T
    Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medullary Thyroid Carcinoma Associated with Germline RET
    Xu JY; Grubbs EG; Waguespack SG; Jimenez C; Gagel RF; Sosa JA; Sellin RV; Dadu R; Hu MI; Trotter CS; Jackson M; Rich TA; Hyde SM; Sherman SI; Cote GJ
    Thyroid; 2016 Dec; 26(12):1744-1751. PubMed ID: 27673361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early, Prophylactic Thyroidectomy in Hereditary Medullary Thyroid Carcinoma: A 26-year Monoinstitutional Experience.
    Pelizzo MR; Torresan F; Boschin IM; Nacamulli D; Pennelli G; Barollo S; Rubello D; Mian C
    Am J Clin Oncol; 2015 Oct; 38(5):508-13. PubMed ID: 24064755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
    Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medullary thyroid carcinoma: long-term outcomes of surgical treatment.
    Abraham DT; Low TH; Messina M; Jackson N; Gill A; Chou AS; Delbridge L; Learoyd D; Robinson BG; Sidhu S; Sywak M
    Ann Surg Oncol; 2011 Jan; 18(1):219-25. PubMed ID: 20878247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition.
    Elisei R; Cosci B; Romei C; Agate L; Piampiani P; Miccoli P; Berti P; Basolo F; Ugolini C; Ciampi R; Nikiforov Y; Pinchera A
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5823-7. PubMed ID: 15531548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation?
    Machens A; Spitschak A; Lorenz K; Pützer BM; Dralle H
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):801-5. PubMed ID: 21711375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients.
    Niccoli-Sire P; Murat A; Rohmer V; Franc S; Chabrier G; Baldet L; Maes B; Savagner F; Giraud S; Bezieau S; Kottler ML; Morange S; Conte-Devolx B;
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3746-53. PubMed ID: 11502806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791.
    Frank-Raue K; Machens A; Scheuba C; Niederle B; Dralle H; Raue F;
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):259-63. PubMed ID: 18248648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.